PFO
ORMP icon

Pioneer Family Office’s Oramed Pharmaceuticals ORMP Stock Holding History

Pioneer Family Office’s Portfolio ORMP Stock Details ORMP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$14.4K Hold
3,000
– – 0.01% 107
2026
Q1 		$10.2K Hold
3,000
– – 0.01% 107
2025
Q4 		$8.55K Buy
+3,000
New +$7.74K 0.01% 130

Other funds holding ORMP

Mercer Global Advisors
Mercer Global Advisors Denver, Colorado $80.9B AUM 26.08% 1-Year Est. Return
AF
Aquamarine Financial George Town $1.81B AUM 38.21% 1-Year Est. Return
GIA
Gem Investment Advisors Teaneck, New Jersey $163M AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
M
Murchinson Toronto, Ontario, Canada $725M AUM 82.02% 1-Year Est. Return
BCM
BML Capital Management Zionsville, Indiana $176M AUM 123.21% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.6B AUM 109.3% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Pioneer Family Office's ORMP Position: Q2 2026 in Review

Pioneer Family Office held its Oramed Pharmaceuticals (ORMP) position steady in Q2 2026 at 3,000 shares worth $14.4K. The position accounts for 0.01% of the portfolio, ranked #107.

Pioneer Family Office first reported a position in ORMP in Q4 2025 and has held it in 3 quarters since. 84 funds tracked by Wall St. Rank hold ORMP as of Q2 2026.

  • Pioneer Family Office held 3,000 shares of Oramed Pharmaceuticals worth $14.4K as of Q2 2026.
  • Pioneer Family Office left its Oramed Pharmaceuticals share count unchanged in Q2 2026.
  • Oramed Pharmaceuticals made up 0.01% of Pioneer Family Office's portfolio in Q2 2026, its #107 holding.
  • Pioneer Family Office first reported a position in Oramed Pharmaceuticals in Q4 2025 and has held it in 3 quarters since.
  • 84 funds tracked by Wall St. Rank held Oramed Pharmaceuticals as of Q2 2026.

Based on Pioneer Family Office's 13F filing for Q2 2026, filed 28 Jul 2026.